Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Certain soaps and other skin care products may irritate hidradenitis suppurativa (HS), whereas others can help manage the condition and its symptoms. HS is a chronic skin condition that causes ...

One key opportunity for growth of the hidradenitis Suppurativa market is the untapped potential found in emerging countries with growing healthcare infrastructure and treatment availability. This ...

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, ...

—Megan Rogge, MD, of McGovern Medical School, UTHealth Houston, explains the need for specific biomarkers in HS, noting that ones like ESR and CRP, while often elevated in these patients, are ...

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...

Detailed price information for Avalo Therapeutics Inc (AVTX-Q) from The Globe and Mail including charting and trades.